FDA alert renews concerns about Oncopeptides’ Pepaxto

[cafead]

via Another shoe dropped on Oncopeptides AB when the U.S. FDA issued an alert July 28 citing trial data showing an increased risk of death with the company’s only marketed drug, Pepaxto, used in combination with dexamethasone to treat multiple myeloma.

article source